Premium
TREATMENT OF MYCOSIS FUNGOIDES WITH OK‐432
Author(s) -
Sawada Yoko,
Ohashi Masaru
Publication year - 1977
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1977.tb00993.x
Subject(s) - mycosis fungoides , dermatology , medicine , lymphoma
Up to the present no other therapeutic means besides local X‐ray or beta‐ray irradiation and anticancer drugs for the treatment of patients with mycosis fungoides, especially when the condition has progressed to secondary involvement of the lymph nodes, has been found. A recent clinical trial of OK‐432 injected locally into cutaneous tumors of a patient with this disease resulted in a conspicuous contraction not only of the tumors injected but of other tumors as well along with significant regression of lymphadenomas. No serious adverse reaction was observed other than low‐grade fever and heavy‐headedness. These results suggest host‐mediated and direct antitumor effects of OK‐432 as the possible underlying mechanisms. The efficacy of OK‐432 in reducing the size of the tumors without causing any serious adverse effects indicate the potential usefulness of this drug for the treatment of mycosis fungoides.